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Brenda K. Zierler, PhD,a,b,d and Darryl T. Gray, MD, ScD,c,d,e,f Seattle, Wash
The current healthcare environment requires the evaluation of both the costs and benefits of alternative interventions for
a given clinical problem. Given the increased interest in the economic evaluation of healthcare interventions, this article
briefly defines various forms of economic evaluations and describes some useful steps for conducting appraisals of
cost-effectiveness analyses. Studies of competing methods of treatment of abdominal aortic aneurysms greater than 5 cm
are used as a clinical example of interest to the readers of this Journal. Rather than actually conducting such an analysis
with existing data, we describe the principles for conducting or reviewing an economic analysis with factitious data. (J
Vasc Surg 2003;37:226-34.)
A first-year surgery resident describes a new patient
seen in the clinic as a 75-year-old man with an asymptom-
atic 5-cm abdominal aortic aneurysm (AAA). The patient
had an myocardial infarction at age 63 years but now has
good exercise tolerance. The patient also has mild hyper-
tension with a blood pressure of 165/88 mm Hg with two
medications. The patient does not have diabetes, and his
renal function is normal. The patient smokes one half of a
pack of cigarettes per day. The resident asks whether an
open surgical repair (OSR) rather than an endovascular
repair (EVR) of the AAA would be more cost effective.
The attending physician, who is skeptical of the newer,
less-invasive EVR method and of all of the associated
follow-up studies that monitoring its outcome necessitates,
says, “Yes, it is. The endografts cost about $12,000 to
$15,000 at our hospital, and the cost of these grafts offsets
the extended length of stay for OSR, which is about 9 days
at our institution, compared with 3 days for EVR. But there
are also many late problems with the endografts that re-
quire ongoing diagnostic studies and possibly additional
interventions. So, you have to add the costs of identifying
and treating possible leaks and another $16,000 for an
open repair if the EVR fails. Our combined mortality and
long-term morbidity rate of 2% for OSR is similar to EVR
rates reported in the literature, so I am quite confident that
OSR is more cost effective than EVR of AAAs.”
One can use this clinical example to illustrate the prin-
ciples of cost-effectiveness analysis as applied to a vascular
surgery question. The attending physician’s statements
about which intervention would be more cost effective for
the treatment of AAAs raise more questions than they
answer, such as:
Has he conducted a formal economic comparison?
What assumptions are being made?
Is he quoting charges or costs?
What are the sources for the effectiveness data?
What were the primary outcomes of interest?
How accurate are the estimates for determining the com-
bined mortality and morbidity rates for OSR of AAAs at
his institution?
What is the time horizon for analyzing his data?
Is he quoting results for comparable populations of pa-
tients, such that differences in mortality and morbidity
rates reflect treatment effects rather than patient char-
acteristics?
Although OSR for AAA is a relatively safe procedure in
some patient groups,1 EVR was developed to avoid the risk
of open abdominal surgery in patients who were poor
operative candidates. EVR exemplifies new technology for
which financial and clinical implications must be evaluated
in the current environment.2 The medical literature in-
creasingly includes economic analyses3 and guidelines for
conducting, reporting, and reviewing such studies.4-10
However, adherence to these guidelines in the cardiovas-
cular surgery literature has been variable.11
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A literature search identified 14 English-language arti-
cles that compared costs and outcomes of OSR and EVR of
AAAs.12-25 An informal review indicated substantial room
for improvement in adherence to principles of economic
analysis. For example, claims made in a number of articles
about the cost effectiveness or cost benefit of one strategy
or the other were not well supported by the accompanying
data.
The goals of this article are to briefly define various
forms of economic evaluations and to describe some useful
steps for conducting an appraisal of a cost-effectiveness
analysis, with a clinical example of interest to the readers of
this Journal. Our intent is not to actually conduct such an
analysis with existing data but to describe the principles for
conducting or reviewing an economic analysis with realistic
data.12-25 The controversy about treatment of AAAs less
than 5 cm or between 5 cm and 6 cm is beyond the scope of
this discussion. For the purpose of this paper and as an
academic exercise only, we have arbitrarily chosen 5 cm as
the threshold for intervention in comparing OSR with
EVR. Although watchful waiting may also be an appropri-
ate alternative for some AAAs between 5 and 5.5 cm, we
have not considered this as an alternative in our example.
However, it is important to note that if a real cost-effective-
ness analysis were being conducted, the size threshold for
intervention and the methods used for determination of
AAA size, along with alternative interventions for compar-
isons, would need to be stated explicitly.
OVERVIEW OF ECONOMIC EVALUATIONS:
BASIC DEFINITIONS
For a given level of available resources, the goal of
maximizing total aggregate health outcomes assumes that
improvement in health status may be achieved through
clinical interventions that have some measurable cost, pro-
vided their relative cost effectiveness is properly assessed.
One value of formal cost analyses is that they force explicit
consideration of the benefits to be anticipated from such
interventions and of the costs incurred to achieve them.
Various treatment alternatives can be compared in terms of
cost and outcome estimates and value tradeoffs to be made
in light of relevant ethical, political, and other consider-
ations.
The most basic form of comparative cost analysis is a
simple cost comparison, which merely asks how much two
competing interventions cost. This first step may help de-
termine whether or not further investigation is warranted.
However, results of such an analysis cannot be meaning-
fully interpreted without information on the clinical value
of the approaches also being considered; a procedure not
worth doing is not worth doing well (ie, efficiently).8 Thus,
simple cost comparisons represent departure points rather
than destinations.
Cost-effectiveness analysis and cost-benefit analysis are
two approaches that simultaneously consider costs and
outcomes of therapy. Confusion regarding the proper use
of these terms is widespread, and studies that are labeled as
cost-effectiveness analyses are often in fact cost-benefit
analyses, and vice versa.26 Cost-benefit and cost-effective-
ness analyses are similar in that they both quantify the
monetary cost of the clinical intervention. The major dis-
tinction between these two approaches is that cost-benefit
analyses require both costs and benefits to be described in
monetary units (generally currency) and cost-effectiveness
analysis imposes no such requirement on the expression of
benefits.8 One attractive feature of cost-benefit analysis is
that cost-benefit ratios for interventions with entirely dif-
ferent clinical objectives may be compared directly (eg,
comparing the cost-benefit ratio of creating a new endovas-
cular center with that of starting a new dialysis center). This
is important when decisions on assigning available re-
sources to various treatments need to be made. Not sur-
prisingly, use of cost-benefit methods to express the bene-
fits of interventions in monetary terms can be extremely
complex.
Although cost-effectiveness analysis also measures costs
in monetary units, the clinical outcomes are left in natural
units rather than being converted to currency. These units
can range from satisfying physiologic criteria (eg, absolute
or relative reduction in) to achieving a stated clinical objec-
tive (eg, successful exclusion of an AAA) or to avoiding or
prolonging the interval before some undesirable conse-
quence (eg, rupture of a small AAA). The cost-effectiveness
approach avoids valuing such outcomes in terms of cur-
rency but is restricted to comparisons of interventions with
goals that can be expressed in the same units (eg, subse-
quent changes in expected mortality).9
Clinicians and policymakers implicitly assign monetary
values to outcomes by choosing whether or not to provide
specific clinical services. For example, the decision to un-
dertake a therapeutic regimen that improves mean survival
by 1 year for every $50,000 spent implies that a life-year is
worth at least $50,000. If an available intervention with
which 1 additional life-year can be saved at a cost of
$500,000 is not undertaken, it may be inferred that the
decision maker does not consider this outcome to be worth
the required expenditure. However, such decisions are not
always made consistently, in that some interventions with
higher costs per life-year saved may be provided and others
with lower costs per life-year saved are not.8,9
Cost-minimization analysis may be considered to be a
special type of cost-effectiveness analysis in which one first
establishes that the clinical outcomes of two interventions
are equal. The focus then is placed on identification of the
option with the lower cost. However, this requires that the
equivalence of outcomes for the two approaches (ie, the
absence of clinically and statistically significant differences)
be proven and not just assumed.8
Cost-utility analysis is a more comprehensive approach
in which the clinical outcomes are expressed as utilities, in
the form of preference-weighted units such as the com-
monly used quality-adjusted life-years (QALYs; described
subsequently), rather than only as unadjusted effectiveness
measures such as crude survival. In economic comparisons,
health outcomes are the end results of the interventions
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performed with the goal of affecting the health status of the
patient population or hypothetic cohort, as measured from
the time of the intervention to the end of the observational
period (or death).27 Individuals or society may have a desire
or preference for a given outcome, to which they may be
said to assign a utility value, although sometimes the terms
utility, preference, and value are used interchangeably.
Several different methods (eg, standard gamble, time-trade
off, rating scale) are used to determine the value that
investigators assign to a given health state or health benefit.
Preference-based methods involve judgements about the
value placed on a particular health state and yield a single
score that is scaled from 0.0 to 1.0 (where 0 usually means
death and 1 usually means perfect health).8,9,27
The use of QALYs allows potential differences in sur-
vival and morbidity attainable with different interventions
to be compared with a single measure that reflects tradeoffs
between them. The quality weights must meet three criteria
to be useful for generating QALYs. They must be: 1,
anchored on two required points (usually perfect health
and death); 2, based on preferences for the health states
(eg, with greater values assigned to more preferred states);
and 3, measured on an interval scale (eg, with weight of 1 as
perfect health and weight of 0 as death).9 Note that some
might consider severe intractable pain or a debilitating
stroke to be “worse than death” and use these outcomes as
0 anchors, with death assigned some value such as 0.1. In
any case, quality adjustment weights for each health state
are multiplied by the time in that state and then summed to
calculate the number of quality adjusted life-years. Even if
reliable data are available on crude life expectancy after the
interventions of interest, the quality adjustment itself can
be a subjective exercise.8,9 More and more cost analyses
now follow current recommendations that studies consider
utilities or preferences for individual outcomes such as
survival with versus without procedure complications or
treatment side effects,8,9,27 rather than just crude survival,
for example. Finally, it should be noted that the term
cost-effectiveness analysis is increasingly used to describe
studies that are, strictly speaking, cost-utility analyses.9
Cost-consequence analysis is a less restrictive form of
comparative cost analysis. In a cost-consequence analysis,
one provides information about various costs (eg, provider
costs, patient out-of-pocket costs, payer costs) and out-
comes (eg, survival, complications, clinical success rates).
However, the readers are left to decide which combination
of costs and outcomes to combine to generate the cost-
effectiveness ratios most relevant to their own perspec-
tives.28
USE OF PUBLISHED GUIDELINES FOR
PERFORMING ECONOMIC ANALYSES OF AAA
REPAIR
With a checklist that was published in 1996 by Drum-
mond et al8 we will describe the principles for conducting
or reviewing an economic analysis with published studies as
the example to capture issues particularly relevant to eval-
uations of EVR and OSR of AAAs, as shown subsequently
(Table).
Define a question completely and pose it in an
answerable form. Ideally, this should specify the clinical
strategies compared, time horizons, measures of clinical
effectiveness, target patient populations, and cost-analysis
perspective. The question should be asked in a manner that
considers both costs and outcomes. The question “Is OSR
more costly than EVR of AAAs?” is an incomplete cost-
effectiveness question because the decision maker also
needs to know the differences in the effectiveness of the two
interventions. A more focused question might be “From a
societal medical care perspective, is OSR more cost effective
than EVR for the initial repair of asymptomatic unruptured
AAAs (5 cm in diameter) in providing 2-year survival free of
repeat aneurysm-related interventions?” The question
should be specific, and the authors should also identify the
target population eligible for both interventions (eg, 70-
year-old men).
The clinical strategies to be compared, along with
measures of their clinical effectiveness and outcomes,
should be clearly stated. Examples of clinical consequences
for the two strategies include mortality (expressed as crude
survival and QALYs), myocardial infarction, pulmonary
complications, renal failure, graft infection, wound dehis-
cence, continued aneurysm sac growth, further rupture,
and stroke.
The time horizon in which costs and outcomes are
measured in a cost-effectiveness analysis should be clearly
stated.8 The time horizon in the previous example was 2
years. Ideally, the time horizon of an analysis should extend
far enough into the future to capture major economic and
health outcomes whether they are intended and not (in the
example given, to include the impact of later diagnostic
procedures, surveillance, and therapeutic interventions).
The target population of interest should be identified.
Existing data may or may not be available for a particular
population (eg, 70-year-old men with AAA  5 cm), and
with a description of the population of interest, the review-
ers are able to judge the validity of the data or perhaps
extrapolate the data into a model for their own studies. The
perspective (decision-making context) of the cost analysis
in the previous example (eg, taking a societal medical care
perspective) includes all healthcare costs relevant to pa-
tients, payers, and society.
Comprehensively describe the competing alterna-
tives to be measured. True cost-effectiveness analyses are
intrinsically comparative, as interventions can only be cost-
effective relative to specified alternatives. Given the rate at
which vascular procedures evolve, it will be important to
clearly describe the operative approaches being compared
in a given study of OSR versus EVR. Especially if accumu-
lating experience indicates divergent purchase prices and
outcomes for various stents and bifurcated grafts manufac-
tured by various companies for use in EVR, it will be
important to distinguish among them when considering
costs, frequencies of use, and outcomes of different grafts.
Alternately, the decision to aggregate costs or the results of
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use of different grafts in the analysis should be acknowl-
edged and justified. The rationale for excluding specific
options (eg, watchful waiting for patients with aneu-
rysms  5 cm) may be widely accepted, but it is important
to state that such options were considered but rejected as
not appropriate and give the reasons.
Establish the effectiveness of the programs or ser-
vices. It cannot be emphasized enough that the design of
a study influences the amount of bias and confounding
present and, therefore, the study’s internal validity. Authors
should clearly state the design of the study and then de-
scribe the data sources used in determining the effective-
ness measures or other endpoints of an intervention that
were measured to allow the reader to judge the validity of
the data and the applicability of the cost-comparison anal-
ysis. Aside from performing primary research, investigators
can also generate clinical effectiveness data from systematic
reviews of clinical trials or formal quantitative syntheses of
the literature (metaanalyses).9,10 In the evaluation of clin-
ical effectiveness for OSR and EVR, the study would first
have to be restricted to include a population that was
appropriate for both EVR and OSR (eg, to patients without
contraindications to general anesthesia) and the success of
achieving the stated clinical objective (preventing rupture
of AAA) would need to be assessed. The rates of repeat
intervention observed during specified postprocedure fol-
low-up should also be tracked. Assessments of perioperative
mortality or complications capture procedure safety but are
not adequate to measure procedure effectiveness.
Regarding OSR and EVR, initial reports on EVR of
AAA claimed that it was a cost-effective alternative to OSR
because of the decreased length of stay and the lower rate of
postoperative complications.14-17,22 However, recent
questions about its durability and effectiveness over time
reflect concerns as to whether or not it is more cost effective
than OSR in the long term.23,24 Previous studies indicated
that EVR uses fewer resources and is therefore cost saving
relative to OSR during the initial hospitalization period.
However, additional interventions from clinical failures
have been reported.24
The morbidity and mortality rates for OSR of AAAs
have been well documented in large randomized controlled
or prospective trials.16,29 However, EVR morbidity and
mortality rates have generally been based on hypothetic
models with unpublished data (eg, abstract proceedings
from scientific meetings) or from consecutive cases from
single institutions.12 A cost-effectiveness analysis (actually a
cost-utility analysis) was chosen by Patel et al12 as the type
of economic evaluation to be used to answer the question
of whether EVR of AAA is a cost-effective alternative to
OSR. The alternatives (OSR and EVR) differ in both costs
and effects, and an incremental cost-effectiveness ratio
(ICER; to be defined) was calculated to address this ques-
tion.
Outcome and cost differences must be reasonably as-
cribable to treatment, rather than other factors. Although
uncommon in procedure evaluations,30 this assessment is
best achieved by randomizing patients to the therapies
being compared. Nonrandomized studies may suffer from
confounding by clinical indication, where clinical features
influencing treatment choices also affect outcome, inde-
pendent of any actual treatment effect.31 For example, in
concurrent intrainstitutional nonrandomized comparative
studies of EVR versus OSR, eligible patients presumably
underwent EVR. Patients ineligible for EVR (eg, because
of unsuitable anatomy) who therefore underwent OSR
differed from patients for EVR in ways that potentially
affected outcome. This selective referral would therefore
confound assessment of treatment effects of EVR versus
OSR, and similar processes could complicate interpretation
of results of single-arm series of EVR or OSR as well.
Ideally, selective use of EVR over OSR in institutions where
both procedures are concurrently available should be ex-
plicitly addressed. Analyses on the basis of literature data
may be forced to include consecutive series (especially of
EVR) from papers that do not describe the criteria used to
select patients in whom EVR was performed.
Given the possibility that outcome differences could
reflect dissimilarities in patient characteristics rather than in
treatment effectiveness, treatment group comparability in
relevant parameters (eg, gender, age, specific comorbidities
affecting operative risk) is essential. This should include
specifying criteria (eg, threshold of hypertension, evidence
of diabetes treated with oral agents or insulin, current
versus any history of tobacco use) used to establish the
presence of risk factors. However, the mere absences of
statistically significant differences in measured factors do
not prove treatment group similarity, especially in studies
with limited statistical power.32 Also, unless measured vari-
ables capture key patient characteristics (eg, aneurysm mor-
phology, systemic risk factors) influencing original treat-
ment choice and outcome, any analysis of risk factors is of
limited value in showing prognostic similarities in the
groups being compared. Alternatively, studies can adjust
for residual confounding with various analytic approaches,
including logistic regression or propensity scoring.33
Even nonrandomized comparisons should follow the
intention-to-treat principle commonly used to analyze re-
sults of randomized controlled trials.34 The primary analy-
sis should ascribe costs and outcomes to the original treat-
ment group for patients in whom any AAA repair attempt is
started but then converted to another procedure. For ex-
ample, it is not appropriate to exclude patients in whom
EVR was unsuccessful or converted to OSR or to ascribe
their results (successes or failures) to the OSR ultimately
performed. Results on the basis of final treatment or those
restricted to costs of successful interventions may also be
examined, but such analyses should clearly be secondary.
Identify important and relevant costs and conse-
quences for each alternative. EVR studies should cap-
ture all costs consistent with the specified analytic perspec-
tive, including those of relevant diagnostic tests. It is
reasonable to either include or exclude tests common to
both procedures, as long as this is done consistently. Usage
and costs should be included for preoperative diagnostic
tests preferentially performed with one treatment method
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or the other (eg, duplex ultrasound scan, computed tomo-
graphic [CT] scanning with/without contrast, arteriogra-
phy, or spiral CT scanning). A base case scenario should
include costs of more extensive follow-up (eg, more fre-
quent CT scans or duplex scans in the first year and then
yearly) for EVR because postoperative surveillance is a
major additional cost for this procedure. Hospital perspec-
tive analyses of healthcare costs should estimate institu-
tional costs, including graft and other material purchase
prices, equipment purchase, personnel costs, and hospital
overhead.9 Although studies that take the hospital perspec-
tive would properly exclude costs of care provided by
nonsalaried physicians or physician assistants, such studies
should include costs of these personnel if they are hospital
employees.
Societal perspective analyses of healthcare costs of EVR
versus OSR should include hospital costs, as noted previ-
ously, and costs of observed involvement of multiple spe-
cialists (ie, cardiac or vascular surgeons, anesthesiologists,
radiologists, and other physicians) and of physician-em-
ployed or hospital-employed physician assistants if applica-
ble. Operating room times that differ for EVR and OSR
would generate cost differences reflecting variable duration
of anesthesiologist or surgeon involvement and higher
surgeon reimbursement for EVR relative to OSR, such that
surgeon costs (captured by reimbursement of some other
approach) should be included. Exclusion of costs that are
similar for both procedures (eg, surgeon reimbursement if
it is the same for both procedures under some payment
plans) might not affect net cost differences from a societal
perspective. However, if frequencies of repeat procedures
or treated complications differ, ignoring surgeon costs will
distort treatment strategy costs.
It is now recommended that cost analyses take a
broader societal perspective that includes capture of patient
out-of-pocket healthcare and related costs, nonmedical
economic costs of lost productivity (eg, lost wages), and
costs that healthcare providers incur when caring for pa-
tients.9 Aside from citing the literature source (including
specifying the use of local versus national averages of Medi-
care physician reimbursement rates) of external cost data
used, authors should clearly indicate the nature of costs
being included (eg, including versus excluding postdis-
charge nursing home care when considering prolonged
convalescence after AAA repair).
The study design should also reasonably capture key
clinical outcomes of interest. In studies of EVR versus OSR,
clinical consequences of interest for both procedures would
include mortality, myocardial infarction, pulmonary com-
plications, renal failure, continued aneurysm sac growth to
some specified diameter, aneurysm rupture, and stroke.24
For EVR, consequences requiring intervention would in-
clude graft thrombosis or occlusions requiring thromboly-
sis or reoperation. Endoleaks are of importance if they
require additional interventions such as stenting, coil place-
ments, or conversion to OSR. Postoperative interventions
of interest after OSR include reoperation for hemorrhage
or dehiscence, recurrent aneurysms, and graft infection.
It is important to establish consistent criteria for the
duration of short-term (eg, within 30 days after surgery)
versus longer term (eg, 2 years or more) follow-up versus
lifetime follow-up. Authors should clarify methods used to
address censoring (eg, total lifetime AAA repair costs or
outcomes being unknown for patients still alive or lost to
follow-up at the end of the study), which can have various
effects on frequencies of outcomes and on cost estimates.34
When modeling long-term outcomes, it is also important
to distinguish between observed follow-up and extrapo-
lated estimates on the basis of modeling.9,27
One situation potentially complicating tracking of costs
and outcomes over time is that patients may spend time in
various health states or levels of wellness such as being well,
sick, or dead, with attendant costs associated with each
state. Although conventional decision trees just consider
the long-term probability of attaining each state, an ap-
proach called Markov modeling allows consideration of
probabilities of transitioning among states during short
time intervals (Markov cycles)9 and then aggregating costs
or quality-adjusted survival associated with the total time
spent in each state.8,9,27
Costs and consequences should be measured accu-
rately in appropriate units. To allow readers to better
estimate costs for their settings, resource use should also be
measured in appropriate units (eg, length of operating
room stays in hours or total hospital stays in days) and
presented separately from costs. Resource use is then mul-
tiplied by reasonable estimates of costs per unit of resource
use to generate costs for individual care components. Cur-
rency is the best summary measure of aggregate resource
use costs. Estimates of costs for care provided in different
calendar years (especially those from the literature) should
be expressed in constant year (eg, 2002) dollars with the
Medical Care component of the local or regional Con-
sumer Price Index.35 Clarity of methods and results would
be enhanced by also expressing costs in dollars from the
original year in which the data were collected.
Outcomes of interest would include proportions of
patients with AAA repairs successful in excluding the aneu-
rysmal section of aorta, as measured with intraprocedural
imaging or with freedom from subsequent rupture or re-
peat interventions. Success of the procedure is a separate
issue from the occurrence of certain complications (unto-
ward consequences, such as a myocardial infarction), which
may or may not occur, independent of the success of the
procedure. Major complications (eg, renal failure) should
be distinguished from minor complications (eg, superficial
wound infections). Complications relevant to AAA repair
could include all-cause mortality, myocardial infarction,
pulmonary complications, limb ischemia requiring major
amputation, renal failure, graft infection, wound dehis-
cence, continued AAA sac growth, rupture, and
stroke.12-25 It is important to note the duration of fol-
low-up and the cost components included (eg, inclusion of
inpatient and outpatient facility and physician care costs,
nursing home costs, costs of lost productivity). Studies also
need to identify specific outcomes (eg, one or more key
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primary outcomes or a composite such as 2-year survival
free of rupture or of repeat intervention) for use in calcu-
lating cost-effectiveness ratios (described subsequently).
The costs and consequences should be valued cred-
ibly according to the stated cost analysis perspective.
Studies reporting hospital costs need to specify cost esti-
mate sources (eg, true production costs, hospital-wide or
department-specific cost to charge ratios).36 Costs of usage
of C-arm fluoroscopy and intravascular ultrasound scan
should be based on observations or clearly articulated as-
sumptions regarding amortized equipment purchase prices
and related technologist and radiologist time. Although
detailed activity-based cost analysis of the use of diagnostic
equipment, technologists, and radiologists37,38 may be be-
yond the scope of a given study, reasonable and unbiased
estimates of costs associated with such imaging should be
made.
Studies measuring societal perspective medical care
costs should combine hospital production costs or reim-
bursement with physician costs associated with specific
treatment-related tasks, as estimated with Resource Based
Relative Value Scales39 (reflecting the quantity and inten-
sity of physician effort expended in providing treatment),
observed time spent in patient care multiplied by compen-
sation and practice expenses expressed per unit time, or
reimbursement (eg, Medicare fee schedules). Billed charges
do not adequately represent costs, as charges represent
neither true costs of providing care nor the reimbursement
actually provided by insurers or patients.36 If charges are
used because of the absence of better data, then the defi-
ciencies of charges as a measure of cost should be clearly
acknowledged.
Measured outcomes should also have been captured
comprehensively. For example, analyses capturing postdis-
charge outcomes should include admissions to other facil-
ities (eg, via review of referring physician office records).
Costs and outcomes should be adjusted for differ-
ential in timing. If the time horizon extends beyond the
interval for which primary outcomes data are available, then
modeled data must be used in the analysis.27 Initial cost-
effectiveness analyses comparing OSR with EVR of AAAs
have used only short-term time horizons up to this point in
time because there were no long-term outcomes data (pri-
mary data) available or the authors were only interested in
determining the differences in length of hospitalization and
costs of initial care.13-15,17-19 More recently, cost-effective-
ness analyses with a long-term time horizon incorporating
modeled data have been conducted.12 If the analysis is not
extended far enough in the future to capture important
differences in cost or outcomes, then short-term results
may not accurately reflect eventual outcomes.8
Costs observed beyond 1 year of follow-up for individ-
ual patients should be discounted to present value (eg, at
3%/y).8,9 This is independent of inflation and reflects9
potential interest or investment income associated with
receiving a given dollar amount 2 years from now rather
than today. For studies following individual patients less
than 1 year, discounting is deemed not applicable. For
studies with longer follow-up, the discount rate should be
stated and the reason for choosing a particular rate should
be justified. Although costs are generally always dis-
counted, discounting of health outcomes is controversial;
however, an explanation should be provided if costs and
outcomes are not discounted.9 A discussion of the contro-
versies surrounding discounting of treatment effects is be-
yond the scope of this paper.
An incremental analysis of costs and consequences
of alternatives should be performed. Ideally, studies
should measure both costs and clinical effectiveness. Those
finding one treatment to be more expensive but more
effective should present ICERs that quantify net cost in-
creases relative to net improvements in specified outcomes.
For example, studies finding EVR to generate higher 1-year
survival free of the need for AAA repair at higher average
cost than OSR could express these results as mean incre-
mental costs per added year of survival free of untoward
events (including major complications, reinterventions).
This is illustrated in the following sample calculation on the
basis of factitious data.
Where:
CostEVR  mean lifetime cost per EVR patient (including
costs of future care)  $27,000
CostOSR  mean lifetime cost per OSR patient (including
costs of future care)  $20,000
EffEVRmean (modeled) lifetime effectiveness of the EVR
strategy  7.8 QALYs
EffOSRmean (modeled) lifetime effectiveness of the OSR
strategy  7.5 QALYs
Then:
CostEVR  CostOSR
EffEVR  EffOSR

$27,000  $20,000
7.8  7.5 QALYs

$7,000
0.30 QALYs
 $23,333/QALY
This result indicates that, relative to OSR, EVR has an
ICER of $23,333/QALY. This means that each additional
$23,333 spent with EVR rather than OSR should “buy”
1.0 additional QALYs. The interpretation of such a ratio
(eg, whether or not it is considered to represent good
“value for money”) should be addressed in the discussion
(see The presentation and discussion of results should
include issues that are of most concern to potential users).
One procedure could be superior to the alternative in
either the cost or outcome dimension and also be at least as
good, if not better, in the other dimension. In such cases,
the superior procedure dominates the alternative. Domi-
nance is relatively unusual but, when present, is an appro-
priate justification for not calculating ICERs.8,9,27
Allowance should be made for uncertainty in the
estimates of cost and consequences. Levels of uncer-
tainty are associated with cost-effectiveness analyses be-
cause of the multiple pieces of information being combined
(natural history of the disease, effectiveness and costs of
interventions, preferences regarding health outcomes,
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long-term results of interventions). To reach defensible
study conclusions, authors must assume that the true values
for all parameters are known or that available figures are
unbiased estimates of the true value and that the character-
istics of the population are known. Authors should report
the uncertainty associated with any observed costs or out-
come differences.9
For stochastic data, details of statistical tests performed
(including assumptions regarding normal distributions)
should be provided along with confidence intervals for
point estimates of individual results and calculated IC-
ERs.40-42 Appropriate measures of central tendency (eg,
means versus medians) of costs and confidence intervals for
outcomes frequencies (eg, mortality, graft infection) need
to be provided. If applicable, an analysis of costs and
outcomes adjusted for differences in risk factors should be
performed. A distinction should be made between nonsig-
nificant results that are clinically or economically important
but reflect small sample size and those that reflect signifi-
cant differences that are clinically or economically unimpor-
tant.
To assess the effects of the various assumptions made in
a cost-effectiveness analysis, a sensitivity analysis should be
performed.8,9,27,40,42 Different approaches to sensitivity
analyses include one-way or univariate sensitivity analyses
and multiway or multivariate sensitivity analyses. One-way
sensitivity analyses assess how changing values of single
parameters within ranges consistent with available clinical
or economic data alter the base case ICER.9 An analysis is
said to be sensitive to values of a particular variable if
changing its value (consistent with the data at hand) affects
the conclusion of the analysis (eg, which treatment is
favored). Conversely, the analysis is said to be robust or
insensitive to values of that variable if changes within a
reasonable range do not alter the conclusion.42
In a multivariate sensitivity analysis, the expected out-
come is determined for different combinations of estimates
of the values of either two or three variables (two-way or
three-way sensitivity analysis, respectively) while holding all
other variables at their base case values. If one-way or
multiway sensitivity analyses indicate that conclusions are
sensitive to reasonable changes in key parameter values,
then authors should be appropriately circumspect about
the strength of their conclusions and may consider seeking
better data to reduce uncertainty about the values of those
parameters. Conversely, having results that are robust over
reasonable ranges of multiple parameters increases one’s
confidence in the study conclusions, regardless of the value
of the individual parameters. Calculating confidence inter-
vals for ICERs should also be done to increase the confi-
dence in the study conclusion.
The presentation and discussion of results should
include issues that are of most concern to potential
users. It is important to answer all components of the cost
comparison study question (eg, “From a societal medical
care perspective, is OSR more cost-effective than EVR for
the initial repair of asymptomatic unruptured AAAs (5 cm
in diameter) in providing 2-year survival free of repeat
aneurysm-related interventions?”). Although no study can
address all concerns of interest to all readers, the discussion
should be reasonably comprehensive. Conclusions should
be consistent with data-driven results and the proper terms
such as cost-effective[ness] should be used. Assertions of
cost-effectiveness require support by data on clinical effec-
tiveness and cost. This includes a discussion as to whether
or not the ICER is sufficiently low as to be consistent with
those of other interventions that society considers cost
effective. Procedures do not have to be dominant or cost
saving to be cost effective. The threshold value of
$60,000/QALY quoted by Patel et al12 reflects a widely
used convention. ICERs below such a value favor classify-
ing the procedure of interest as cost effective and therefore
worthy of dissemination. Conversely, ICER values above
such thresholds may identify treatments with effects that do
not justify the costs incurred. Because this particular thresh-
old value in part reflects conversion into current dollars of
the classic ICER threshold used to justify Federal funding
of dialysis in the End Stage Renal Disease program begun
25 years ago, it is admittedly arbitrary and may not be an
appropriate cutoff for every situation.
Ideally, discussions should also compare the study re-
sults with those of previously published reports, acknowl-
edging similarities and differences in study design, patient
population, cost perspective, and outcomes. Studies should
also consider the generalizability and potential policy im-
plications of their results. For example, authors studying
repair of AAAs greater than or equal to 5 cm in diameter
might be tempted to apply their findings to smaller aneu-
rysms (AAA less than 5 cm) as well. Any discussion of the
implications of such an assumption should acknowledge
the risks of extrapolating results to a larger or different
population that was not studied directly and may differ in
gender distribution, operative risks, and other features. The
authors should also discuss the broader implication of their
study results (eg, implications for decision makers with
other perspectives).
Most importantly, the authors need to acknowledge
the study limitations and their effect on the study conclu-
sion (eg, using charge data to measure costs, comparing
different populations, using data from unpublished studies,
conducting a one-way sensitivity analysis instead of a mul-
tivariate one). As mentioned earlier, the design of a study
influences the amount of bias and confounding present
and, therefore, a study’s internal validity, so it is paramount
that the authors consider the design of the study in which
they abstracted effectiveness data when discussing the re-
sults.
CONCLUSION
Given the increased awareness of the importance of cost
effectiveness in healthcare, there has been a growth in the
number of published economic evaluations in recent years.
In response to concerns about deficiencies in the method-
ology of published studies, there has been a concerted
effort to use established guidelines or standards when con-
ducting or reviewing economic evaluations. This paper has
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briefly defined the various forms of economic evaluations
and used a clinical example familiar to the readers of this
Journal to describe some useful steps for conducting an
appraisal of a cost-effectiveness analysis. Our intent was not
to actually conduct such an analysis with existing data but
to describe the principles for conducting or reviewing an
economic analysis with realistic data from the literature. We
used a well-known checklist that was published in 1996 by
Drummond et al8 that has been widely used by authors and
editors of several journals (eg, British Medical Journal,
Journal of the American Medical Association, New En-
gland Journal of Medicine, Health Economics).43-46 The
guidelines or policies for conducting cost comparisons that
have been published dictate that investigators document
the degree to which appropriate methodology supports
their results.
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